Spinal Surgery Trial Results

Deltex Medical Group PLC
26 September 2006



                            Deltex Medical Group plc

  French clinical trial demonstrates utility of CardioQ(TM) in spinal surgery


26 September 2006 Deltex Medical Group plc ('Deltex Medical' or the 'Company'),
the UK's leading haemodynamic monitoring company, today highlights the
presentation of a clinical trial undertaken by Dr Payen and colleagues at
Grenoble hospital into the use of Deltex Medical's CardioQ monitor. The trial
results were made public at the European Society of Intensive Care Medicine
(ESICM) conference in Barcelona earlier today.

Patients undergoing spinal surgery are placed face down on the operating table
('prone position') throughout the surgery. The prone position can have an
adverse effect on the patient's blood circulation ('haemodynamics') and
potentially lead to complications. It is therefore important to be able to
identify and treat any haemodynamic changes in these patients quickly and
safely.

The trial results showed that it is possible to monitor patients having spinal
surgery in the prone position effectively and safely using the minimally
invasive CardioQ.

Deltex Medical's chief executive, Andy Hill, commented:

'This trial confirms for the first time that the CardioQ works in spinal surgery
- where rapid diagnosis and intervention is required to prevent potentially
life-threatening complications. Multiple randomised trials have demonstrated
that the CardioQ is the only intra-operative haemodynamic monitor which can
reduce complications and length of hospital stay.'

For further information, please contact:-

Deltex Medical Group plc                     01243 774 837
Nigel Keen, Nigel Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director


Gavin Anderson & Company                     0207 554 1400
Deborah Walter
Marie Cairney
Jodie Reilly


Charles Stanley Securities                   020 7149 6457
Philip Davies


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the 
CardioQ which have repeatedly:-

   •    Validated the results of the Monitor against known standards for
        measuring cardiac output, demonstrating that the technology works

   •    Proved that the CardioQ works in a wide range of surgical procedures

   •    Demonstrated that the Company's technology provides significant health
        and economic benefits by helping to reduce post-operative complications 
        and length of hospital stays by an average of 30 to 40 per cent for a 
        wide range of patients.


                      This information is provided by RNS
            The company news service from the London Stock Exchange